EIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase

Experimental Cell Research

Volumn 319, Issue 13, 2013, Pages 2103-2112

  Sundin, Tabetha ^a   Peffley, Dennis ^a   Hentosh, Patricia ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE GREENVILLE   (United States)

Author keywords

EIF4E overexpression; Oncogene addiction; Oncogenic shock; PI3K Akt mTOR pathway; Telomerase activity; Telomerase reverse transcriptase

Indexed keywords

INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PERILLYL ALCOHOL; PROTEIN KINASE B; RAPAMYCIN; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL DENSITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING;

CRICETULUS GRISEUS; EUKARYOTA;

EID: 84879889714     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.05.029     Document Type: Article

References (61)

1. von der Haar T., Gross J.D., Wagner G., McCarthy J.E. The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat. Struct. Mol. Biol. 2004, 11:503-511.
2. Rozen F., Edery I., Meerovitch K., Dever T.E., Merrick W.C., Sonenberg N. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol. Cell. Biol. 1990, 10:1134-1144.
3. Cutler N.S., Pan X., Heitman J., Cardenas M.E. The TOR signal transduction cascade controls cellular differentiation in response to nutrients. Mol. Biol. Cell 2001, 12:4103-4113.
4. Sengupta S., Peterson T.R., Sabatini D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40:310-322.
5. Chakravarti N., Kadara H., Yoon D.J., Shay J.W., Myers J.N., Lotan D., Sonenberg N., Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev. Res. 2010, 3:331-338.
6. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 2004, 91:1420-1424.
7. Peffley D.M., Sharma C., Hentosh P., Buechler R.D. Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells. Arch. Biochem. Biophys. 2007, 465:266-273.
8. Farazuddin M., Sharma B., Khan A.A., Joshi B., Owais M. Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles. Int. J. Nanomed. 2012, 7:35-47.
9. Lebedeva I.V., Su Z.Z., Vozhilla N., Chatman L., Sarkar D., Dent P., Athar M., Fisher P.B. Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Mol. Cancer Ther. 2008, 7:2042-2050.
10. Mo H., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. 2004, 229:567-585.
11. da Fonseca C.O., Schwartsmann G., Fischer J., Nagel J., Futuro D., Quirico-Santos T., Gattass C.R. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg. Neurol. 2008, 70:259-266. discussion 266-267.
12. da Fonseca C.O., Simao M., Lins I.R., Caetano R.O., Futuro D., Quirico-Santos T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J. Cancer Res. Clin. Oncol. 2011, 137:287-293.
13. Morgan-Meadows S., Dubey S., Gould M., Tutsch K., Marnocha R., Arzoomanin R., Alberti D., Binger K., Feierabend C., Volkman J., Ellingen S., Black S., Pomplun M., Wilding G., Bailey H. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother. Pharmacol. 2003, 52:361-366.
14. Stratton S.P., Alberts D.S., Einspahr J.G., Sagerman P.M., Warneke J.A., Curiel-Lewandrowski C., Myrdal P.B., Karlage K.L., Nickoloff B.J., Brooks C., Saboda K., Yozwiak M.L., Krutzsch M.F., Hu C., Lluria-Prevatt M., Dong Z., Bowden G.T., Bartels P.H. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev. Res. 2010, 3:160-169.
15. De Benedetti A., Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199.
16. Thumma S.C., Kratzke R.A. Translational control: a target for cancer therapy. Cancer Lett. 2007, 258:1-8.
17. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
18. Sundin T., Peffley D.M., Gauthier D., Hentosh P. The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. Biochimie 2012, 94:2639-2648.
19. Buechler R.D., Peffley D.M. Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis. Mol. Carcinogenesis 2004, 41:39-53.
20. Jimeno A., Rudek M.A., Kulesza P., Ma W.W., Wheelhouse J., Howard A., Khan Y., Zhao M., Jacene H., Messersmith W.A., Laheru D., Donehower R.C., Garrett-Mayer E., Baker S.D., Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J. Clin. Oncol. 2008, 26:4172-4179.
21. Hou M., Xu D., Bjorkholm M., Gruber A. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin. Chem. 2001, 47:519-524.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
23. Kruk P.A., Orren D.K., Bohr V.A. Telomerase activity is elevated in early S phase in hamster cells. Biochem. Biophys. Res. Commun. 1997, 233:717-722.
24. Weinberg R.A. The Biology of Cancer 2007, Garland Science, New York.
25. De Benedetti A., Joshi B., Graff J.R., Zimmer S.G. CHO cells transformed by the translation factor eIF-4E display increased c-myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Differ. 1994, 2:347-371.
26. Nie L., Wu G., Zhang W. Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem. Biophys. Res. Commun 2006, 339:603-610.
27. Tian Q., Stepaniants S.B., Mao M., Weng L., Feetham M.C., Doyle M.J., Yi E.C., Dai H., Thorsson V., Eng J., Goodlett D., Berger J.P., Gunter B., Linseley P.S., Stoughton R.B., Aebersold R., Collins S.J., Hanlon W.A., Hood L.E. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol. Cell. Proteomics 2004, 3:960-969.
28. Culjkovic B., Tan K., Orolicki S., Amri A., Meloche S., Borden K.L. The eIF4E RNA regulon promotes the Akt signaling pathway. J. Cell Biol. 2008, 181:51-63.
29. Peffley D.M., Gayen A.K. Plant-derived monoterpenes suppress hamster kidney cell 3-hydroxy-3-methylglutaryl coenzyme a reductase synthesis at the post-transcriptional level. J. Nutr. 2003, 133:38-44.
30. Sundin T., Peffley D.M., Hentosh P. Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin. Mol. Cell. Biochem. 2013, 375:97-104.
31. Peffley D., Hentosh P. Plant-derived isoprenoids mediate regulation of mTOR signaling in tumor cells. Natural Compounds as Inducers of Cell Death 2012, vol. 1:373-400. Springer Publishing.
32. Khambu B., Uesugi M., Kawazoe Y. Translational repression stabilizes messenger RNA of autophagy-related genes. Genes Cells 2011, 16:857-867.
33. Ross J. mRNA stability in mammalian cells. Microbiol. Rev. 1995, 59:423-450.
34. Ross J. A hypothesis to explain why translation inhibitors stabilize mRNAs in mammalian cells: mRNA stability and mitosis. BioEssays 1997, 19:527-529.
35. Andrei M.A., Ingelfinger D., Heintzmann R., Achsel T., Rivera-Pomar R., Luhrmann R. A role for eIF4E and eIF4E-transporter in targeting mRNPs to mammalian processing bodies. RNA 2005, 11:717-727.
36. Ferraiuolo M.A., Basak S., Dostie J., Murray E.L., Schoenberg D.R., Sonenberg N. A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay. J. Cell Biol. 2005, 170:913-924.
37. Chen Y.C., Chiang H.Y., Yang M.H., Chen P.M., Chang S.Y., Teng S.C., Vanhaesebroeck B., Wu K.J. Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. J. Mol. Med. 2008, 86:401-412.
38. Chen Y.C., Su Y.N., Chou P.C., Chiang W.C., Chang M.C., Wang L.S., Teng S.C., Wu K.J. Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 2005, 280:32505-32511.
39. Sagan D., Mortl S., Muller I., Eckardt-Schupp F., Eichholtz-Wirth H. Enhanced CD95-mediated apoptosis contributes to radiation hypersensitivity of NBS lymphoblasts. Apoptosis 2007, 12:753-767.
40. Alessi D.R., Kozlowski M.T., Weng Q.P., Morrice N., Avruch J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol. 1998, 8:69-81.
41. Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C., Hemmings B.A., Thomas G. Phosphorylation and activation of p70s6k by PDK1. Science 1998, 279:707-710.
42. El-Osta M.A., Idkowiak-Baldys J., Hannun Y.A. Delayed phosphorylation of classical protein kinase C (PKC) substrates requires PKC internalization and formation of the pericentrion in a phospholipase D (PLD)-dependent manner. J. Biol. Chem. 2011, 286:19340-19353.
43. Fenton T.R., Gout I.T. Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 2011, 43:47-59.
44. Satheesha S., Cookson V.J., Coleman L.J., Ingram N., Madhok B., Hanby A.M., Suleman C.A., Sabine V.S., Macaskill E.J., Bartlett J.M., Dixon J.M., McElwaine J.N., Hughes T.A. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol. Cancer 2011, 10:19.
45. Settleman J. Oncogene addiction. Curr. Biol. 2012, 22:R43-44.
46. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res. 2008, 68:3077-3080.
47. Willis R.E. Human gene control by vital oncogenes: revisiting a theoretical model and its implications for targeted cancer therapy. Int. J. Mol. Sci. 2012, 13:316-335.
48. Zhou J.P., Chen X., Feng S., Luo S.D., Pan Y.L., Zhong L., Ji P., Wang Z.R., Ma S., Li L.L., Wei Y.Q., Yang S.Y. Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers. PloS One 2011, 6:e28930.
49. Ito T., Okusaka T., Ikeda M., Igarashi H., Morizane C., Nakachi K., Tajima T., Kasuga A., Fujita Y., Furuse J. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn. J. Clin. Oncol. 2012, 42:903-911.
50. Bergmann L., Goebell P.J., Kube U., Kindler M., Herrmann E., Janssen J., Schmitz J., Weikert S., Steiner G., Jakob A., Staehler M.D., Steiner T., Overkamp F., Albrecht M., Guderian G., Doehn C. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. Onkologie 2013, 36:95-100.
51. van den Eertwegh A.J., Karakiewicz P., Bavbek S., Rha S.Y., Bracarda S., Bahl A., Ou Y.C., Kim D., Panneerselvam A., Anak O., Grunwald V. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. Urology 2013, 81:143-149.
52. Sun Y., Rha S., Lee S.H., Guo J., Ueda T., Qin S., Naito S., Cincotta M., Tokushige K., Akaza H. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn. J. Clin. Oncol. 2012, 42:836-844.
53. Mills J.J., Chari R.S., Boyer I.J., Gould M.N., Jirtle R.L. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res. 1995, 55:979-983.
54. Elson C.E., Peffley D.M., Hentosh P., Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med. 1999, 221:294-311.
55. Yang H., Dou Q.P. Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer. Curr. Drug Targets 2010, 11:733-744.
56. Khan N., Afaq F., Khusro F.H., Adhami V.M., Suh Y., Mukhtar H. Dual inhibition of PI3K/AKT and mTOR signaling in human non-small cell lung cancer cells by a dietary flavonoid fisetin. Int. J. Cancer 2011, 130:1695-1705.
57. Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P. mTOR kinase structure, mechanism and regulation. Nature 2013, 497:217-223.
58. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
59. Rosenwald I.B., Kaspar R., Rousseau D., Gehrke L., Leboulch P., Chen J.J., Schmidt E.V., Sonenberg N., London I.M. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. 1995, 270:21176-21180.
60. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266.
61. Shay J.W., Gazdar A.F. Telomerase in the early detection of cancer. J. Clin. Pathol. 1997, 50:106-109.